64
Participants
Start Date
September 30, 2009
Primary Completion Date
May 31, 2015
Study Completion Date
May 31, 2015
Cyclophosphamide
"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response,or unacceptable toxicity."
Liposomal-encapsulated doxorubicin
"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.~Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.~Therapy will continue until maximum response or unacceptable toxicity."
University General Hospital of Alexandroupolis, Alexandroupoli
"IASO General Hospital of Athens, 1st Dep of Medical Oncology", Athens
"Laikon General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine", Athens
"Marika Iliadis Hospital of Athens, Dep of Medical Oncology", Athens
"Metaxa's Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology", Athens
401 Military Hospital of Athens, Athens
Air Forces Military Hospital of Athens, Athens
University Hospital of Crete, Heraklion
State General Hospital of Larissa, Dep of Medical Oncology, Larissa
"Diabalkaniko hospital, Thessaloniki", Thessaloniki
": Theagenion Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology", Thessaloniki
Lead Sponsor
Hellenic Oncology Research Group
OTHER